This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.
Get full access to this article
View all access options for this article.
References
1.
AttwoodS.E., LewisC.J., BronderC.S., MorrisC.D., ArmstrongG.R., WhittamJ.Eosinophilic oesophagitis: A novel treatment using montelukast. Gut.2003; 52(2): 181–185.
2.
LucendoA.J., de RezendeL.C., Jiménez-ContrerasS.Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig Dis Sci.2011; 56(12) 3551–3558.
3.
DellonE.S., GonsalvesN., HiranoI., FurutaG.T., LiacourasC.A., KatzkaD.A.; American College of Gastroenterology. ACG clinical guideline: Evidence based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol.2013; 108(5): 679–692.
4.
LiacourasC.A., FurutaG.T., HiranoI.Eosinophilic esophagitis: Updated consensus recommendations for children and adults. J Allergy Clin Immunol.2011; 128(1): 3–20.e6.
FurutaG.T., LiacourasC.A., CollinsM.H.; First International Gastrointestinal Eosinophil Research Symposium (FIGERS) Subcommittees. Eosinophilic esophagitis in children and adults: A systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology.2007; 133(4): 1342–1363. ■
